Display options
Share it on

Gastrointest Cancer. 2018;8:13-23. doi: 10.2147/GICTT.S125940. Epub 2018 Mar 22.

Emerging treatment options for .

Gastrointestinal cancer : targets and therapy

Carling Ursem, Chloe E Atreya, Katherine Van Loon

Affiliations

  1. Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA.

PMID: 29628780 PMCID: PMC5889076 DOI: 10.2147/GICTT.S125940

Abstract

The personalization of cancer care is rooted in the premise that there are subsets of patients with tumors harboring clinically relevant targets for patient-specific treatments. Colorectal cancer (CRC) is a disease that has historically been notable for its dearth of biomarkers that are predictive of response to targeted therapies. In recent years,

Keywords: BRAF mutation; colon cancer; molecular targets; targeted therapy

Conflict of interest statement

Disclosure The authors report no other conflicts of interest in this work.

References

  1. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  2. Clin Cancer Res. 2008 Jun 1;14(11):3408-15 - PubMed
  3. Cancer Epidemiol Biomarkers Prev. 2008 Jul;17(7):1774-80 - PubMed
  4. J Clin Oncol. 2010 Jan 20;28(3):466-74 - PubMed
  5. Int J Cancer. 2011 May 1;128(9):2075-84 - PubMed
  6. N Engl J Med. 2010 Aug 26;363(9):809-19 - PubMed
  7. Cancer. 2011 Oct 15;117(20):4623-32 - PubMed
  8. Lancet. 2011 Jun 18;377(9783):2103-14 - PubMed
  9. Clin Cancer Res. 2012 Feb 1;18(3):890-900 - PubMed
  10. Cancer Res. 2012 Feb 1;72(3):779-89 - PubMed
  11. Nature. 2012 Jan 26;483(7387):100-3 - PubMed
  12. Eur J Cancer. 2012 Jul;48(10):1466-75 - PubMed
  13. Cancer Discov. 2012 Mar;2(3):227-35 - PubMed
  14. Lancet. 2012 Jul 28;380(9839):358-65 - PubMed
  15. Nature. 2012 Jul 18;487(7407):330-7 - PubMed
  16. Clin Cancer Res. 2013 Feb 1;19(3):657-67 - PubMed
  17. J Natl Cancer Inst. 2013 Aug 7;105(15):1151-6 - PubMed
  18. Nat Genet. 2013 Oct;45(10):1113-20 - PubMed
  19. Lancet Oncol. 2013 Nov;14(12):1208-15 - PubMed
  20. Cancer. 2014 Aug 1;120(15):2316-24 - PubMed
  21. Clin Cancer Res. 2014 Oct 15;20(20):5322-30 - PubMed
  22. N Engl J Med. 2014 Oct 23;371(17):1609-18 - PubMed
  23. Clin Cancer Res. 2015 Mar 15;21(6):1313-20 - PubMed
  24. Eur J Cancer. 2015 Mar;51(5):587-94 - PubMed
  25. Cancer Discov. 2015 Apr;5(4):358-67 - PubMed
  26. Br J Cancer. 2015 Jun 9;112(12):1888-94 - PubMed
  27. N Engl J Med. 2015 Jun 25;372(26):2509-20 - PubMed
  28. Ann Oncol. 2015 Oct;26(10):2092-7 - PubMed
  29. J Natl Cancer Inst. 2015 Jul 09;107(10):null - PubMed
  30. N Engl J Med. 2015 Aug 20;373(8):726-36 - PubMed
  31. Lancet Oncol. 2015 Oct;16(13):1306-15 - PubMed
  32. J Clin Oncol. 2015 Dec 1;33(34):4023-31 - PubMed
  33. J Clin Oncol. 2015 Dec 1;33(34):4032-8 - PubMed
  34. BMC Cancer. 2015 Oct 24;15:779 - PubMed
  35. Br J Cancer. 2016 Jan 12;114(1):30-6 - PubMed
  36. Clin Cancer Res. 2017 Jan 1;23(1):104-115 - PubMed
  37. J Natl Compr Canc Netw. 2016 Dec;14(12):1536-1543 - PubMed
  38. Ann Oncol. 2017 Mar 1;28(3):562-568 - PubMed
  39. BMC Cancer. 2017 Jan 9;17(1):38 - PubMed
  40. Cancer Discov. 2017 Jun;7(6):610-619 - PubMed
  41. Eur J Cancer. 2017 Jul;79:50-60 - PubMed
  42. J Clin Oncol. 2017 Aug 10;35(23):2624-2630 - PubMed
  43. JAMA. 2017 Jun 20;317(23):2392-2401 - PubMed
  44. Lancet Oncol. 2017 Sep;18(9):1182-1191 - PubMed
  45. Ann Oncol. 2017 Sep 1;28(9):2128-2134 - PubMed
  46. Cancer Discov. 2018 Apr;8(4):428-443 - PubMed

Publication Types

Grant support